Sirolimus suppresses circulating fibrocytes in idiopathic pulmonary fibrosis in a randomized controlled crossover trial
BACKGROUND Fibrocytes are BM-derived circulating cells that traffic to the injured lungs and contribute to fibrogenesis. The mTOR inhibitor, sirolimus, inhibits fibrocyte CXCR4 expression, reducing fibrocyte traffic and attenuating lung fibrosis in animal models. We sought to test the hypothesis tha...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
American Society for Clinical investigation
2023-04-01
|
| Series: | JCI Insight |
| Subjects: | |
| Online Access: | https://doi.org/10.1172/jci.insight.166901 |
| _version_ | 1797634315606032384 |
|---|---|
| author | Diana C. Gomez-Manjarres Dierdre B. Axell-House Divya C. Patel John Odackal Victor Yu Marie D. Burdick Borna Mehrad |
| author_facet | Diana C. Gomez-Manjarres Dierdre B. Axell-House Divya C. Patel John Odackal Victor Yu Marie D. Burdick Borna Mehrad |
| author_sort | Diana C. Gomez-Manjarres |
| collection | DOAJ |
| description | BACKGROUND Fibrocytes are BM-derived circulating cells that traffic to the injured lungs and contribute to fibrogenesis. The mTOR inhibitor, sirolimus, inhibits fibrocyte CXCR4 expression, reducing fibrocyte traffic and attenuating lung fibrosis in animal models. We sought to test the hypothesis that short-term treatment with sirolimus reduces the concentration of CXCR4+ circulating fibrocytes in patients with idiopathic pulmonary fibrosis (IPF).METHODS We conducted a short-term randomized double-blind placebo-controlled crossover pilot trial to assess the safety and tolerability of sirolimus in IPF. Participants were randomly assigned to sirolimus or placebo for approximately 6 weeks, and after a 4-week washout, they were assigned to the alternate treatment. Toxicity, lung function, and the concentration of circulating fibrocytes were measured before and after each treatment.RESULTS In the 28 study participants, sirolimus resulted in a statistically significant 35% decline in the concentration of total fibrocytes, 34% decline in CXCR4+ fibrocytes, and 42% decline in fibrocytes expressing α-smooth muscle actin, but no significant change in these populations occurred on placebo. Respiratory adverse events occurred more frequently during treatment with placebo than sirolimus; the incidence of adverse events and drug tolerability did not otherwise differ during therapy with drug and placebo. Lung function was unaffected by either treatment, with the exception of a small decline in gas transfer during treatment with placebo.CONCLUSION As compared with placebo, short-term treatment with sirolimus resulted in reduction of circulating fibrocyte concentrations in participants with IPF, with an acceptable safety profile.TRIAL REGISTRATION ClinicalTrials.gov, accession no. NCT01462006.FUNDING NIH R01HL098329 and American Heart Association 18TPA34170486. |
| first_indexed | 2024-03-11T12:06:53Z |
| format | Article |
| id | doaj.art-ae52790f2c464809ac9fc165eeb74b7c |
| institution | Directory Open Access Journal |
| issn | 2379-3708 |
| language | English |
| last_indexed | 2024-03-11T12:06:53Z |
| publishDate | 2023-04-01 |
| publisher | American Society for Clinical investigation |
| record_format | Article |
| series | JCI Insight |
| spelling | doaj.art-ae52790f2c464809ac9fc165eeb74b7c2023-11-07T16:25:31ZengAmerican Society for Clinical investigationJCI Insight2379-37082023-04-0188Sirolimus suppresses circulating fibrocytes in idiopathic pulmonary fibrosis in a randomized controlled crossover trialDiana C. Gomez-ManjarresDierdre B. Axell-HouseDivya C. PatelJohn OdackalVictor YuMarie D. BurdickBorna MehradBACKGROUND Fibrocytes are BM-derived circulating cells that traffic to the injured lungs and contribute to fibrogenesis. The mTOR inhibitor, sirolimus, inhibits fibrocyte CXCR4 expression, reducing fibrocyte traffic and attenuating lung fibrosis in animal models. We sought to test the hypothesis that short-term treatment with sirolimus reduces the concentration of CXCR4+ circulating fibrocytes in patients with idiopathic pulmonary fibrosis (IPF).METHODS We conducted a short-term randomized double-blind placebo-controlled crossover pilot trial to assess the safety and tolerability of sirolimus in IPF. Participants were randomly assigned to sirolimus or placebo for approximately 6 weeks, and after a 4-week washout, they were assigned to the alternate treatment. Toxicity, lung function, and the concentration of circulating fibrocytes were measured before and after each treatment.RESULTS In the 28 study participants, sirolimus resulted in a statistically significant 35% decline in the concentration of total fibrocytes, 34% decline in CXCR4+ fibrocytes, and 42% decline in fibrocytes expressing α-smooth muscle actin, but no significant change in these populations occurred on placebo. Respiratory adverse events occurred more frequently during treatment with placebo than sirolimus; the incidence of adverse events and drug tolerability did not otherwise differ during therapy with drug and placebo. Lung function was unaffected by either treatment, with the exception of a small decline in gas transfer during treatment with placebo.CONCLUSION As compared with placebo, short-term treatment with sirolimus resulted in reduction of circulating fibrocyte concentrations in participants with IPF, with an acceptable safety profile.TRIAL REGISTRATION ClinicalTrials.gov, accession no. NCT01462006.FUNDING NIH R01HL098329 and American Heart Association 18TPA34170486.https://doi.org/10.1172/jci.insight.166901Pulmonology |
| spellingShingle | Diana C. Gomez-Manjarres Dierdre B. Axell-House Divya C. Patel John Odackal Victor Yu Marie D. Burdick Borna Mehrad Sirolimus suppresses circulating fibrocytes in idiopathic pulmonary fibrosis in a randomized controlled crossover trial JCI Insight Pulmonology |
| title | Sirolimus suppresses circulating fibrocytes in idiopathic pulmonary fibrosis in a randomized controlled crossover trial |
| title_full | Sirolimus suppresses circulating fibrocytes in idiopathic pulmonary fibrosis in a randomized controlled crossover trial |
| title_fullStr | Sirolimus suppresses circulating fibrocytes in idiopathic pulmonary fibrosis in a randomized controlled crossover trial |
| title_full_unstemmed | Sirolimus suppresses circulating fibrocytes in idiopathic pulmonary fibrosis in a randomized controlled crossover trial |
| title_short | Sirolimus suppresses circulating fibrocytes in idiopathic pulmonary fibrosis in a randomized controlled crossover trial |
| title_sort | sirolimus suppresses circulating fibrocytes in idiopathic pulmonary fibrosis in a randomized controlled crossover trial |
| topic | Pulmonology |
| url | https://doi.org/10.1172/jci.insight.166901 |
| work_keys_str_mv | AT dianacgomezmanjarres sirolimussuppressescirculatingfibrocytesinidiopathicpulmonaryfibrosisinarandomizedcontrolledcrossovertrial AT dierdrebaxellhouse sirolimussuppressescirculatingfibrocytesinidiopathicpulmonaryfibrosisinarandomizedcontrolledcrossovertrial AT divyacpatel sirolimussuppressescirculatingfibrocytesinidiopathicpulmonaryfibrosisinarandomizedcontrolledcrossovertrial AT johnodackal sirolimussuppressescirculatingfibrocytesinidiopathicpulmonaryfibrosisinarandomizedcontrolledcrossovertrial AT victoryu sirolimussuppressescirculatingfibrocytesinidiopathicpulmonaryfibrosisinarandomizedcontrolledcrossovertrial AT mariedburdick sirolimussuppressescirculatingfibrocytesinidiopathicpulmonaryfibrosisinarandomizedcontrolledcrossovertrial AT bornamehrad sirolimussuppressescirculatingfibrocytesinidiopathicpulmonaryfibrosisinarandomizedcontrolledcrossovertrial |